Special Issue

Approaches in Hepatitis Vaccine Design and Vaccination Strategy

Message from the Guest Editor

Hepatitis B virus (HBV) causes both acute and chronic liver diseases. Chronic HBV infection can lead to severe complications. Recent studies suggest that HBV vaccines may offer therapeutic benefits; therefore, there is a need for new strategies to develop more effective treatments and vaccines to control HBV infection. Therapeutic vaccines, particularly hepatitis B, are in development. They are designed to treat chronic infections by stimulating the body's immune system to clear the virus. While no therapeutic vaccine has yet achieved a functional cure, these vaccines are designed differently from preventative ones, often combining multiple viral antigens and sometimes using novel platforms like mRNA to induce a more potent and specific immune response capable of controlling. There is a need for further development of therapeutic vaccines concerning their composition, antigens, dosages, and methods of administration. This Special Issue will focus on addressing vaccine-related issues to achieve the overarching goal of the "Elimination of Hepatitis" in the near future. We look forward to receiving your contributions.

Guest Editor

Dr. Sheikh Mohammad Fazle Akbar

Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan

Deadline for manuscript submissions

30 September 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/259676

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

